Evolving trends in dupilumab use for chronic rhinosinusitis with nasal polyps (CRSwNP): a 4-year cohort analysis

Abstract Chronic rhinosinusitis with nasal polyps (CRSwNP) affects up to 4.5% of the population and is frequently driven by type 2 inflammation. Dupilumab, targeting IL‑4 and IL‑13 pathways, was approved in 2019 as the first biologic for CRSwNP in Germany. This single-center, retrospective study ana...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Patrick Huber, Moritz Gröger, Clemens Stihl, Hanna Frankenberger, Donata Gellrich
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Nature Portfolio 2025-12-01
Sarja:	Scientific Reports
Aiheet:	CRSwNP Dupilumab Chronic rhinosinusitis Biologics
Linkit:	https://doi.org/10.1038/s41598-025-17787-4
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!